20.11.2017


Nanogate
SE Intends to Continue its Course of Expansion With Further Acquisition and to Extend its Global Market Position

06.11.2017


4SC:
First patient enrolled in Phase Ib/II study SENSITIZE of 4SC-202 in melanoma

10.10.2017


4SC:
Resminostat demonstrates potential to significantly alleviate itching in CTCL patients

28.09.2017


Nanogate
SE improves its margin in the first half of the year and expects sales of over EUR 250 million over the medium term

13.09.2017


4SC:
Phase I study of 4SC’s resminostat indicates efficacy in biliary tract cancer

04.02.2016


Nanogate
driving international growth forward – Strong foreign business expected for 2016

21.01.2016


vasopharm
Announces EUR 20 million Fundraising to Progress Treatment for Traumatic Brain Injury

10.10.2015


Nanogate
is „Entrepreneur Of The Year 2015“

23.04.2015


Nanogate
plans to increase sales to over EUR 80 million – Preliminary figures for 2014 exceeded

09.04.2015


Nanogate
expands technology portfolio: creation of a new platform for the multifunctional metallisation of surfaces

23.03.2015


Nanogate
AG: Capital increase agreed

18.02.2015


Nanogate
increases sales by around 27 % and exceeds earnings forecast

05.02.2015


Nanogate
AG: Successful integration of Vogler GmbH

19.01.2015


Nanogate
AG opens up new field of application with a major order for touchpads

06.11.2014


4SC
announces financial results for the first nine months and the third quarter of 2014

03.11.2014


Nanogate
strengthens financial position for growth strategy

24.09.2014


Nanogate
generates sales increase – Operating result improves disproportionately – Order base increased

 

10.09.2014


Nanogate
AG: Growth offensive on innovative metal coatings – establishment of a centre of excellence for the advanced metals division

10.07.2014


Nanogate
AG acquires surface specialist Vogler: expansion of technology portfolio and capacities

18.06.2014


MerLion
completes recruitment in Finafloxacin phase II cUTI trial

26.05.2014


MerLion
Announces a Significant Milestone in the Development of Finafloxacin for Treatment of Acute Otitis Externa

26.02.2014


Nanogate
achieves over EUR 50 million in sales and launches strategy programme with a sales target of EUR 100 million

22.10.2013


vasopharm
Reports Endorsement of Phase III Trial Design in Traumatic Brain Injury by European Medicines Agency

09.10.2013


NANOGATE
AG RECEIVES ORDER FROM MIELE

30.09.2013


NANOGATE
AG: SALES INCREASED BY ALMOST A THIRD, CONSOLIDATED NET INCOME DOUBLED

25.09.2013


NANOGATE
AG PURCHASES SARASTRO GMBH

03.09.2013


NANOGATE
AG: MASS PRODUCTION BEGINS ON SIX DIFFERENT GLAZING COMPONENTS FOR A NEW PREMIUM SUV

22.08.2013


NANOGATE
AG: MAJOR ORDER FOR DESIGN-ORIENTED METAL ENHANCEMENTS

16.07.2013


NANOGATE
ESTABLISHES ITSELF AS A SYSTEMS SUPPLIER (TIER 1 SUPPLIER) FOR A LEADING GLOBAL AUTOMOBILE MANUFACTURER WITH A MAJOR ORDER FOR HIGH-QUALITY PLASTICS

01.07.2013


Nanogate
AG equips industrial facilities with high-performance filter systems

30.06.2013


HeidelbergCapital
and Entrepreneurs Fund lead the takeover of the stake of EMBL Technology Fund in vasopharm GmbH

24.06.2013


vasopharm
Closes Series F Financing Round

19.06.2013


Nanogate
AG: first dividend resolved

05.06.2013


Nanogate
expands structure for strategic growth field of glazing and secures new orders

23.05.2013


Nanogate
AG increases stake in GfO AG

14.05.2013


Nanogate
wins major new order for energy-efficient heating systems

24.04.2013


Nanogate
intends to pay a dividend for the first time

15.03.2013


Nanogate
boosts sales of energy-efficient heating systems

14.03.2013


Another
record year of sales and earnings for Nanogate – EBITDA increased to around EUR 5.6 million

05.03.2013


Nanogate
AG: Production of glazing components under way for premium German manufacturer – Biggest order in the company’s history

14.01.2013


Nanogate
begins exclusive partnership with FILA

09.01.2013


Nanogate
increases equity holding in Plastic-Design

18.12.2012


Nanogate
will supply technology for the global leader in variable focus eyewear

11.12.2012


MerLion
Pharmaceuticals Announces Initiation of first Phase II Clinical Study with Finafloxacin in Patients with Complicated Urinary Tract Infections

21.11.2012


Nanogate
AG successfully places capital increase

08.11.2012


Nanogate
acquires equity holding in plastics specialist Plastic-Design – Considerable growth expected in dynamic market for glazing systems with high-tech plastics

07.11.2012


MerLion
Announces Successful Completion of a Phase I Clinical Study with Intravenously Administered Finafloxacin

25.09.2012


Dynamic
growth for Nanogate AG: EBIT nearly trebled, forecast for 2012 confirmed

17.09.2012


vasopharm’s
Traumatic Brain Injury Drug Exceeds Expectations in Phase IIa Exploratory Clinical Trial

18.04.2012


MerLion
Announces Initiation of a Phase III Clinical Programme to Evaluate Finafloxacin for the Treatment of Acute Otitis Media

19.01.2012


4SC
AG: Cancer compound resminostat meets primary endpoint in Phase II trial in advanced liver cancer ahead of schedule